NASDAQ:AMED - Amedisys Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $274.46
  • Forecasted Upside: 12.29 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$244.43
▲ +3.18 (1.32%)
1 month | 3 months | 12 months
Get New Amedisys Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMED and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMED

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$274.46
▲ +12.29% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Amedisys in the last 3 months. The average price target is $274.46, with a high forecast of $340.00 and a low forecast of $190.00. The average price target represents a 12.29% upside from the last price of $244.43.
Buy
The current consensus among 12 polled investment analysts is to buy stock in Amedisys. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/15/2019
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/14/2019
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/13/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/11/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/9/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/8/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2021BenchmarkBoost Price TargetBuy$275.00 ➝ $325.00N/A
i
2/23/2021BenchmarkBoost Price TargetPositive ➝ Buy$275.00 ➝ $325.00Medium
i
2/8/2021Deutsche Bank AktiengesellschaftBoost Price TargetBuy$275.00 ➝ $340.00Medium
i
1/5/2021TruistBoost Price Target$280.00 ➝ $325.00N/A
i
11/3/2020BarclaysBoost Price TargetOverweight$290.00 ➝ $298.00Medium
i
10/30/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$260.00 ➝ $275.00High
i
10/30/2020Credit Suisse GroupBoost Price TargetOutperform$246.00 ➝ $280.00High
i
9/21/2020OppenheimerBoost Price TargetOutperform$250.00 ➝ $260.00High
i
9/10/2020StephensReiterated RatingEqual Weight$235.00 ➝ $245.00Medium
i
9/2/2020BMO Capital MarketsBoost Price TargetMarket Perform$250.00 ➝ $270.00High
i
8/20/2020BarclaysInitiated CoverageOverweight$290.00 ➝ $290.00High
i
7/30/2020SunTrust BanksBoost Price TargetBuy$260.00 ➝ $270.00Medium
i
7/30/2020BenchmarkBoost Price TargetBuy$210.00 ➝ $250.00Medium
i
Rating by Bill Sutherland at Benchmark Co.
7/30/2020Royal Bank of CanadaBoost Price TargetOutperform$218.00 ➝ $260.00Medium
i
7/30/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$220.00 ➝ $260.00Medium
i
7/30/2020Raymond JamesBoost Price TargetOutperform$210.00 ➝ $255.00Medium
i
7/29/2020Jefferies Financial GroupBoost Price TargetBuy$225.00 ➝ $250.00Medium
i
7/10/2020SunTrust BanksBoost Price TargetBuy$240.00 ➝ $260.00Medium
i
6/18/2020BenchmarkUpgradeHold ➝ Buy$210.00High
i
5/21/2020SunTrust BanksBoost Price TargetBuy$225.00 ➝ $240.00High
i
5/11/2020UBS GroupLower Price TargetNeutral$208.00 ➝ $190.00Low
i
5/11/2020Raymond JamesLower Price TargetOutperform$225.00 ➝ $210.00Medium
i
5/10/2020Royal Bank of CanadaReiterated RatingBuy$218.00Medium
i
5/7/2020BenchmarkDowngradeBuy ➝ HoldHigh
i
4/27/2020OppenheimerReiterated RatingBuy$215.00Medium
i
3/9/2020BenchmarkUpgradeHold ➝ Buy$205.00High
i
2/21/2020StephensBoost Price TargetEqual Weight$180.00 ➝ $200.00Low
i
Rating by Scott Fidel at Stephens
2/21/2020UBS GroupBoost Price TargetNeutral$154.00 ➝ $208.00Low
i
2/21/2020BMO Capital MarketsReiterated RatingMarket Perform$215.00Low
i
Rating by Matthew Borsch at BMO Capital Markets
2/21/2020Credit Suisse GroupBoost Price TargetOutperform$206.00 ➝ $214.00Low
i
Rating by A.J. Rice at Credit Suisse Group AG
2/20/2020SunTrust BanksBoost Price TargetBuy$185.00 ➝ $225.00Low
i
2/20/2020Raymond JamesBoost Price TargetOutperform$200.00 ➝ $225.00Low
i
1/17/2020Credit Suisse GroupInitiated CoverageOutperform$206.00Low
i
1/3/2020Raymond JamesSet Price TargetOutperform$144.00 ➝ $200.00Medium
i
12/18/2019SunTrust BanksBoost Price TargetBuy$175.00 ➝ $185.00Low
i
12/6/2019BMO Capital MarketsInitiated CoverageMarket Perform$170.00Medium
i
11/26/2019Bank of AmericaBoost Price TargetBuy$170.00 ➝ $178.00Low
i
11/1/2019Robert W. BairdUpgradeNeutral ➝ Outperform$140.00 ➝ $160.00High
i
10/22/2019StephensReiterated RatingEqual Weight$145.00Low
i
10/21/2019StephensInitiated CoverageEqual Weight$145.00Low
i
9/16/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy$155.00Low
i
8/5/2019BarclaysBoost Price TargetEqual Weight$120.00 ➝ $125.00High
i
8/2/2019Royal Bank of CanadaBoost Price TargetOutperform$150.00Low
i
8/1/2019OppenheimerBoost Price Target$140.00 ➝ $150.00Low
i
7/15/2019Raymond JamesBoost Price TargetOutperform$140.00 ➝ $144.00Medium
i
7/8/2019Jefferies Financial GroupSet Price TargetBuy$150.00Low
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
5/2/2019Raymond JamesUpgradeMarket Perform ➝ Outperform$140.00High
i
3/21/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$115.00 ➝ $120.00Low
i
3/1/2019Craig HallumLower Price TargetHold$132.00 ➝ $124.00Low
i
3/1/2019SunTrust BanksBoost Price TargetBuy$145.00Low
i
2/5/2019BenchmarkDowngradeBuy ➝ Hold$136.64High
i
Rating by Bill Sutherland at Benchmark Co.
12/14/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$130.00High
i
11/16/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$126.00Medium
i
10/30/2018BenchmarkUpgradeHold ➝ Buy$125.00High
i
Rating by Bill Sutherland at Benchmark Co.
10/26/2018Craig HallumDowngradeBuy ➝ Hold$116.00 ➝ $104.00Medium
i
10/11/2018Robert W. BairdBoost Price TargetNeutral$105.00 ➝ $120.00High
i
10/11/2018SunTrust BanksBoost Price TargetBuy$130.00High
i
10/11/2018Cantor FitzgeraldBoost Price TargetNeutral$117.00 ➝ $125.00High
i
Rating by J. France at Cantor Fitzgerald
9/18/2018Bank of AmericaSet Price TargetBuy$139.00Low
i
Rating by Joanna Gajuk at Bank of America Co.
9/13/2018Cantor FitzgeraldInitiated CoverageNeutral$117.00Low
i
Rating by J. France at Cantor Fitzgerald
9/13/2018Canaccord GenuityInitiated CoverageNeutral$117.00Low
i
8/3/2018Royal Bank of CanadaBoost Price TargetOutperform$115.00Medium
i
7/3/2018Bank of AmericaUpgradeNeutral ➝ Buy$88.00 ➝ $97.00Medium
i
Rating by Joanna Gajuk at Bank of America Co.
6/5/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$73.00 ➝ $78.00Medium
i
6/5/2018StephensReiterated RatingHold$78.00High
i
Rating by Dana Hambly at Stephens
6/5/2018Robert W. BairdBoost Price TargetNeutral ➝ Neutral$67.00 ➝ $72.00High
i
Rating by Whit Mayo at Robert W. Baird
5/9/2018Craig HallumBoost Price TargetBuy$60.00 ➝ $82.00Low
i
5/8/2018Robert W. BairdBoost Price TargetNeutral ➝ Neutral$66.00High
i
Rating by Whit Mayo at Robert W. Baird
3/19/2018Royal Bank of CanadaUpgradeSector Perform ➝ OutperformLow
i
3/1/2018Robert W. BairdSet Price TargetNeutral ➝ Hold$60.00 ➝ $66.00Medium
i
Rating by Whit Mayo at Robert W. Baird
3/1/2018OppenheimerBoost Price TargetOutperform$68.00 ➝ $63.00High
i
2/28/2018Jefferies Financial GroupSet Price TargetBuy$70.00Medium
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
11/21/2017William BlairReiterated RatingOutperformN/A
i
Rating by M. Larew at William Blair
11/10/2017SunTrust BanksReiterated RatingBuy$70.00N/A
i
11/10/2017Robert W. BairdBoost Price TargetNeutral$50.00 ➝ $60.00N/A
i
11/9/2017Craig HallumReiterated RatingBuy$55.00 ➝ $68.00N/A
i
11/9/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$56.00 ➝ $62.00N/A
i
11/9/2017BenchmarkReiterated RatingBuy ➝ HoldN/A
i
11/8/2017MizuhoReiterated RatingBuy$55.00 ➝ $65.00N/A
i
Rating by Sheryl Skolnick at Mizuho
11/2/2017BenchmarkUpgradeHold ➝ Buy$56.00N/A
i
11/2/2017MizuhoUpgradeNeutral ➝ Buy$55.00 ➝ $65.00N/A
i
Rating by Sheryl Skolnick at Mizuho
10/23/2017Royal Bank of CanadaReiterated RatingHoldN/A
i
10/12/2017Jefferies Financial GroupReiterated RatingBuy$60.00N/A
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
10/9/2017SunTrust BanksReiterated RatingBuy$60.00N/A
i
10/4/2017Robert W. BairdReiterated RatingHold$50.00Low
i
9/15/2017OppenheimerReiterated RatingBuy$60.00Low
i
8/21/2017Bank of AmericaInitiated CoverageNeutral ➝ Neutral$55.00Low
i
7/26/2017MizuhoDowngradeBuy ➝ Neutral$50.00High
i
Rating by Sheryl Skolnick at Mizuho
6/5/2017Royal Bank of CanadaReiterated RatingHold$56.00Low
i
5/4/2017StephensBoost Price TargetEqual Weight$50.00 ➝ $54.00Low
i
5/3/2017BenchmarkReiterated RatingHold ➝ Hold$50.00 ➝ $57.00High
i
5/3/2017MizuhoUpgradeNeutral ➝ Buy$65.00High
i
Rating by Sheryl Skolnick at Mizuho
4/28/2017Jefferies Financial GroupReiterated RatingBuy$57.00Low
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
3/3/2017OppenheimerReiterated RatingOutperform$50.00 ➝ $59.00N/A
i
3/1/2017Jefferies Financial GroupBoost Price TargetBuy$50.00 ➝ $57.00N/A
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
3/1/2017MizuhoBoost Price TargetNeutral ➝ Neutral$33.00 ➝ $50.00N/A
i
1/27/2017BenchmarkInitiated CoverageHold$50.00N/A
i
1/17/2017Craig HallumSet Price TargetBuy$60.00N/A
i
Rating by William Bonello at Craig Hallum
1/13/2017Jefferies Financial GroupSet Price TargetBuy$50.00N/A
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
12/16/2016Craig HallumInitiated CoverageBuy$48.00N/A
i
11/9/2016MizuhoDowngradeBuy ➝ NeutralN/A
i
11/7/2016MizuhoUpgradeNeutral ➝ Buy$47.00N/A
i
11/4/2016MizuhoUpgradeNeutral ➝ Buy$47.00N/A
i
11/1/2016Jefferies Financial GroupReiterated RatingBuy$59.00 ➝ $50.00N/A
i
9/11/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
9/6/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
8/3/2016MizuhoDowngradeBuy ➝ Neutral$57.00 ➝ $55.00N/A
i
Rating by Sheryl Skolnick at Mizuho
6/16/2016StephensInitiated CoverageEqual Weight$55.00N/A
i
5/25/2016Jefferies Financial GroupReiterated RatingBuy$59.00N/A
i
5/16/2016Robert W. BairdReiterated RatingHoldN/A
i
5/6/2016Royal Bank of CanadaBoost Price TargetSector Perform$41.00 ➝ $48.00N/A
i
5/4/2016OppenheimerReiterated RatingBuy$56.00N/A
i
Rating by Michael Wiederhorn at Oppenheimer Holdings Inc.
4/11/2016MizuhoReiterated RatingBuy$49.00 ➝ $57.00N/A
i
3/17/2016OppenheimerReiterated RatingOutperform$45.00N/A
i
Rating by Michael Wiederhorn at Oppenheimer Holdings Inc.
3/11/2016MizuhoReiterated RatingBuy$49.00N/A
i
3/10/2016Jefferies Financial GroupReiterated RatingBuy$48.00N/A
i
3/10/2016OppenheimerReiterated RatingOutperform$40.00 ➝ $45.00N/A
i
Rating by Michael Wiederhorn at Oppenheimer Holdings Inc.
(Data available from 3/9/2016 forward)
Amedisys logo
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, or cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 18, 2020, the company owned and operated 479 care centers in 38 states and the District of Columbia. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
Read More

Today's Range

Now: $244.43
$237.81
$251.10

50 Day Range

MA: $287.27
$236.62
$314.16

52 Week Range

Now: $244.43
$132.95
$325.12

Volume

435,840 shs

Average Volume

183,080 shs

Market Capitalization

$8.03 billion

P/E Ratio

48.98

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Amedisys?

The following Wall Street sell-side analysts have issued reports on Amedisys in the last year: Barclays PLC, Benchmark Co., BMO Capital Markets, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Raymond James, Royal Bank of Canada, Stephens, SunTrust Banks, Inc., Truist, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for AMED.

What is the current price target for Amedisys?

13 Wall Street analysts have set twelve-month price targets for Amedisys in the last year. Their average twelve-month price target is $274.46, suggesting a possible upside of 12.3%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting AMED will reach $340.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $190.00 for Amedisys in the next year.
View the latest price targets for AMED.

What is the current consensus analyst rating for Amedisys?

Amedisys currently has 3 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AMED will outperform the market and that investors should add to their positions of Amedisys.
View the latest ratings for AMED.

What other companies compete with Amedisys?

How do I contact Amedisys' investor relations team?

Amedisys' physical mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider's listed phone number is 225-292-2031 and its investor relations email address is [email protected] The official website for Amedisys is www.amedisys.com.